Einzeltreffer — DigiBib

New anti-obesity medications (AOMs) have received widespread acclaim in medical journals and the media, but they also raise critical ethical, public health, and public policy concerns that have largely been ignored. AOMs are very costly, need to be taken by a patient in perpetuity (since significant rebound weight gain otherwise occurs), and threaten to shift resources and focus away from other crucial efforts at obesity treatment and prevention. Many people may feel less motivated to exercise or reduce their caloric consumption, if they assume that obesity is now medically treatable. Policy-makers may similarly come to feel that the solution to the obesity pandemic is simply to prescribe medications and that prevention efforts are far less necessary. These drugs raise concerns about justice (since AOMs will disproportionately benefit the wealthy), medicalization, and marketing. Policy-makers, clinicians, and others need to engage in multipronged educational and policy efforts to address these challenges.

Titel:	Anti-obesity Medications: Ethical, Policy, and Public Health Concerns.
Autor/in / Beteiligte Person:	Klitzman, R ; Greenberg, H
Link:	Full Text Finder (Volltext)
Zeitschrift:	The Hastings Center report, Jg. 54 (2024-05-01), Heft 3, S. 6-10
Veröffentlichung:	2012- : Malden, MA : Wiley-Blackwell ; <i>Original Publication</i>: Hastings-on-Hudson, N. Y., Institute of Society, Ethics and the Life Sciences., 2024
Medientyp:	academicJournal
ISSN:	1552-146X (electronic)
DOI:	10.1002/hast.1588
Schlagwort:	Humans United States Anti-Obesity Agents Obesity drug therapy Public Health ethics Health Policy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Hastings Cent Rep] 2024 May; Vol. 54 (3), pp. 6-10. MeSH Terms: Anti-Obesity Agents* ; Obesity* / drug therapy ; Public Health* / ethics ; Health Policy* ; Humans ; United States References: “New Drugs Could Spell an End to the World's Obesity Epidemic,” editorial, Economist, March 4, 2023. ; W. A. Haseltine, “The End of Obesity: New Weight Loss Drugs Provide Hope to Those Overweight,” Forbes, January 24, 2023. ; H. H. Thorp, “More Questions Than Answers,” Science 382 (2023): 1213. ; Z. J. Ward et al., “Projected U.S. State Level Prevalence of Obesity and Severe Obesity,” New England Journal of Medicine 381 (2019): 2440–50. ; The GBD 2015 Obesity Collaborators, “Health Effects of Overweight and Obesity in 195 Countries over 25 Years,” New England Journal of Medicine 377 (2017): 13–27. ; “Adult Obesity Facts,” Centers for Disease Control and Prevention, last reviewed May 17, 2022, https://www.cdc.gov/obesity/data/adult.html. ; P. Farmaki et al., “Complications of the Type 2 Diabetes Mellites,” Current Cardiology Reviews 16, no. 4 (2020): 249–51. ; A. Okunogbe et al., “Economic Impacts of Overweight and Obesity: Current and Future Estimates for Eight Countries,” BMJ Global Health 6, no. 10 (2021): doi:10.1136/bmjgh-2021-006351. ; “Military Expenditure (% of GDP): 1960-2022,” World Bank, Stockholm International Peace Research Institute (SIPRI), accessed April 12, 2024, https://data.worldbank.org/indicator/MS.MIL.XPND.GD.ZS. ; J. Rosenstock et al., “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA,” Lancet 402 (2023): 529–44. ; J. P. Frias et al., “Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes: A Multicentre, Randomised, Dose-Response, Phase 2 Study,” Lancet 402 (2023): 472–83. ; A. M. Lincoff et al., “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes,” New England Journal of Medicine 389 (2023): 2221–32. ; Frias et al., “Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes.”. ; K. Amin et al., “How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?,” KFF Health Costs, August 17, 2023, https://www.kff.org/health-costs/issue-brief/how-do-prices-of-drugs-for-weight-loss-in-the-u-s-compare-to-peer-nations-prices/. ; E. M. Tichy et al., “National Trends in Prescription Drug Expenditures and Projections for 2023,” American Journal of Health System Pharmacy 80 (2023): 899–913. ; J. Cubanski et al., “FAQs on Health Spending, the Federal Budget, and Budget Enforcement Tools,” KFF Medicare, March 20, 2023, https://www.kff.org/medicare/issue-brief/faqs-on-health-spending-the-federal-budget-and-budget-enforcement-tools/. ; J. J. Darrow and A. S. Kesselheim, “Promoting Competition to Address Pharmaceutical Prices,” Health Affairs, March 15, 2018, https://www.healthaffairs.org/do/10.1377/hpb20180116.967310/. ; Ibid. ; A. Aboulenein, “U.S. Pharmacy Benefit Lobby Group Ramps up Spending as Lawmakers Close In,” Reuters, January 25, 2024, https://www.reuters.com/business/healthcare-pharmaceuticals/us-pharmacy-benefit-lobby-group-ramps-up-spending-lawmakers-close-2024-01-25/. ; C. V. Anekwe et al., “Socioeconomics of Obesity,” Current Obesity Reports 9, no. 3 (2020): 272–79. ; Lincoff, “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.”. ; A. E. Faerber and D. H. Kreling, “Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs,” Journal of General Internal Medicine 29, no. 1 (2014): 110–18; N. Khalil Zadeh, K. Robertson, and J. A. Green, “‘At-Risk’ Individuals’ Responses to Direct to Consumer Advertising of Prescription Drugs: A Nationally Representative Cross-Sectional Study,” BMJ Open 7, no. 12 (2017): doi:10.1136/bmjopen-2017-017865; J. T. DeFrank et al., “Direct-to-Consumer Advertising of Prescription Drugs and the Patient-Prescriber Encounter: A Systematic Review,” Health Communication 35, no. 6 (2020): 739-46; N. Parekh and W. H. Shrank, “Dangers and Opportunities of Direct-to-Consumer Advertising,” Journal of General Internal Medicine 33, no. 5 (2018): 586-87. ; “Obesity is a disease. Let's treat it like one,” LillyDirect™, accessed April 12, 2024, https://lillydirect.lilly.com/obesity; B. Lovelace Jr., M. Vespa, and J. Herzberg, “Eli Lilly Launches Website to Help Patients Get Weight Loss Drugs,” NBC News, January 24, 2024, https://www.nbcnews.com/health/health-news/weight-loss-drug-online-website-eli-lilly-rcna131597. ; P. McCarthy and W. K. Talley, “Evidence on Risk Compensation and Safety Behaviour,” Economics Letters 62, no. 1 (1999): 91–96. ; V. E. Powell et al., “Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation,” Current Infectious Disease Reports 21, no. 8 (2019): 28. ; A. S. Itria et al., “Taxing Sugar-Sweetened Beverages as a Policy to Reduce Overweight and Obesity in Countries of Different Income Classifications: A Systematic Review,” Public Health Nutrition 24 (2021): 5550–60. ; L. Cornelsen, M. Mazzocchi, and R. D. Smith, “Fat Tax or Thin Subsidy? How Price Increases and Decreases Affect the Energy and Nutrient Content of Food and Beverage Purchases in Great Britain,” Social Science & Medicine 230 (2019): 318–27. ; K. Garton, A. M. Throw, and B. Swinburn, “International Trade and Investment Agreements as Barriers to Food Environment Regulation for Public Health Nutrition: A Realist Review,” International Journal of Health Policy and Management 10, no. 12 (2021): 745–65. ; L. O. Gostin, “‘Big Food’ Is Making America Sick,” Milbank Quarterly 93, no. 3 (2016): 480–84. ; Garton, Throw, and Swinburn, “International Trade and Investment Agreements as Barriers to Food Environment Regulation for Public Health Nutrition.”. ; H. Jones et al., “Changes in Diabetes Self-Care Behaviors Make a Difference in Glycemic Control: The Diabetes Stages of Change (DiSC) Study,” Diabetes Care 26, no. 3 (2003): 732–37; J. M. Gómez Puente and M. Martínez-Marcos, “Overweight and Obesity: Effectiveness of Interventions in Adults,” Enfermería Clínica 28, no. 1 (2018): 65-74. ; Ibid. ; Y. Wang et al., “What Childhood Obesity Prevention Programmes Work? A Systematic Review and Meta-Analysis,” Obesity Reviews 16, no. 7 (2015): 547–65. ; Ibid. ; V. Matsudo, “The Role of Partnership in Promoting Physical Activity,” Health Place 18 (2012): 121–22. ; S. L. Gortmaker, S. N. Bleich, and D. R. Williams, “Childhood Obesity Prevention—Focusing on Population-Level Interventions and Equity,” New England Journal of Medicine 390, no. 8 (2024): 681–83. ; H. Greenberg and C. C. Branas, “Bringing Public Health to the Trade Table,” Health Affairs, April 7, 2022, https://www.healthaffairs.org/content/forefront/bringing-public-health-trade-table. ; H. M. Salis, “Genetic Circuity Boots Cell Longevity,” Science 380 (2023): doi:10.1126/science.adh4872. Contributed Indexing: Keywords: bioethics; ethics; obesity; policy; prevention; public health Substance Nomenclature: 0 (Anti-Obesity Agents) Entry Date(s): Date Created: 20240606 Date Completed: 20240606 Latest Revision: 20240606 Update Code: 20240607

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Anti-obesity Medications: Ethical, Policy, and Public Health Concerns.